Alpaslan Dedeoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alpaslan Dedeoglu has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
Bruce G. Jenkins
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
13 shared publications- Ole Andreas Andreassen
Institute of Clinical Medicine, University of Oslo, Oslo, Norway
13 shared publications Neil W. Kowall
Department of Veterans Affairs, VA Boston Healthcare System, Boston, USA
11 shared publicationsIsabel Carreras
Department of Veterans Affairs, VA Boston Healthcare System,150 S Huntington Av, Boston, MA 02130, USA; Department of Neurology, Boston University School of Medicine, 72 E Concord St, Boston, MA 02118, USA; Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA
10 shared publicationsRobert J. Ferrante
Geriatric Research Education and Clinical Center, Bedford VA Medical Center, Bedford, Massachusetts, USA and Department of Neurology, Pathology, and Psychiatry, Boston University School of Medicine, Boston, Massachusetts, USA
10 shared publications- Bruce G. Jenkins
Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, USA
8 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Wiley in Journal of Periodontology
- Vol. 97 (9) , 1965-1979
Aging and periodontitis increase brain dissemination of oral bacteria
Background: The microbiome is a dynamic system that changes throughout life. Studies have revealed the relationship between periodontal disease and the oral microbiota; however, the impact of periodontal disease on the expression of senescence markers and on the inflammaging of the oral and systemic microbiome remains unclear. We hypothesized that aging increases the periodontitis‐induced changes in the oral and systemic microbiome and is accompanied by an altered inflammatory response. Methods: Experimental periodontitis was induced in 18‐month‐old (old) and 8‐month‐old (young) C57BL/6 mice by placing ligatures around the second maxillary molars. Bone morphometric analyses were conducted to assess bone loss. Senescence‐ and inflammatory‐related gene expression in the gingiva was measured by quantitative polymerase chain reaction (qPCR). Serum inflammatory markers were evaluated via immunoassay. Oral, brain, and gut microbial content were analyzed using next‐generation sequencing. Results: Maxillary bone loss was significantly higher in the old mice with periodontal disease than in young mice. Senescence and inflammatory markers were higher in old mice than in young ones, and periodontitis increased their expression. The alpha diversity of the oral and brain microbial communities differed significantly between old and young mice. Treponema denticola , Fusobacterium nucleatum, Porphyromonas gingivalis, P. pasteri , and Prevotella nigrescens were only detected in the brains of old animals with periodontitis. Conclusion: Periodontopathogens and oral commensals are either only found in the brains of old animals with periodontal disease or are more prevalent in the brains of old animals, suggesting that aging and periodontitis may contribute to the dissemination of oral bacteria to the brain. Plain language summary: Aging may increase the periodontitis‐induced changes in the oral and systemic microbiome, which an altered inflammatory response may accompany. Experimental periodontitis was created in old and young mouse models. Bone loss, senescence, and inflammatory gene expression and serum inflammatory markers were assessed in each model, and oral, brain, and gut microbial content was analyzed. Senescence and inflammatory markers were higher in old mice than in young ones, and periodontitis increased their expression. Our results suggested that aging and periodontitis may contribute to the dissemination of oral bacteria to the brain.
- 13 April 2026
- Published by Wiley in Journal of Periodontology
- Vol. 97 (9) , 1965-1979
Open AccessAging and periodontitis increase brain dissemination of oral bacteria
Background: The microbiome is a dynamic system that changes throughout life. Studies have revealed the relationship between periodontal disease and the oral microbiota; however, the impact of periodontal disease on the expression of senescence markers and on the inflammaging of the oral and systemic microbiome remains unclear. We hypothesized that aging increases the periodontitis‐induced changes in the oral and systemic microbiome and is accompanied by an altered inflammatory response. Methods: Experimental periodontitis was induced in 18‐month‐old (old) and 8‐month‐old (young) C57BL/6 mice by placing ligatures around the second maxillary molars. Bone morphometric analyses were conducted to assess bone loss. Senescence‐ and inflammatory‐related gene expression in the gingiva was measured by quantitative polymerase chain reaction (qPCR). Serum inflammatory markers were evaluated via immunoassay. Oral, brain, and gut microbial content were analyzed using next‐generation sequencing. Results: Maxillary bone loss was significantly higher in the old mice with periodontal disease than in young mice. Senescence and inflammatory markers were higher in old mice than in young ones, and periodontitis increased their expression. The alpha diversity of the oral and brain microbial communities differed significantly between old and young mice. Treponema denticola , Fusobacterium nucleatum, Porphyromonas gingivalis, P. pasteri , and Prevotella nigrescens were only detected in the brains of old animals with periodontitis. Conclusion: Periodontopathogens and oral commensals are either only found in the brains of old animals with periodontal disease or are more prevalent in the brains of old animals, suggesting that aging and periodontitis may contribute to the dissemination of oral bacteria to the brain. Plain language summary: Aging may increase the periodontitis‐induced changes in the oral and systemic microbiome, which an altered inflammatory response may accompany. Experimental periodontitis was created in old and young mouse models. Bone loss, senescence, and inflammatory gene expression and serum inflammatory markers were assessed in each model, and oral, brain, and gut microbial content was analyzed. Senescence and inflammatory markers were higher in old mice than in young ones, and periodontitis increased their expression. Our results suggested that aging and periodontitis may contribute to the dissemination of oral bacteria to the brain.
- Open Access
- 26 March 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (9)
Gα11 deficiency increases fibroblast growth factor 23 levels in a mouse model of familial hypocalciuric hypercalcemia
Fibroblast growth factor 23 (FGF23) production has recently been shown to increase downstream of Gα q/11 -PKC signaling in osteocytes. Inactivating mutations in the gene encoding Gα 11 ( GNA11 ) cause familial hypocalciuric hypercalcemia (FHH) due to impaired calcium-sensing receptor signaling. We explored the effect of Gα 11 deficiency on FGF23 production in mice with heterozygous ( Gna11 +/– ) or homozygous ( Gna11 –/– ) ablation of Gna11 . Both Gna11 +/– and Gna11 –/– mice demonstrated hypercalcemia and mildly raised parathyroid hormone levels, consistent with FHH. Strikingly, these mice also displayed increased serum levels of total and intact FGF23 and hypophosphatemia. Gna11 –/– mice showed augmented Fgf23 mRNA levels in the liver and heart, but not in bone or bone marrow, and also showed evidence of systemic inflammation with elevated serum IL-1β levels. Furin gene expression was significantly increased in the Gna11 –/– liver, suggesting enhanced FGF23 cleavage despite the observed rise in circulating intact FGF23 levels. Gna11 –/– mice had normal renal function and reduced serum levels of glycerol-3-phosphate, excluding kidney injury as the primary cause of elevated intact FGF23 levels. Thus, Gα 11 ablation caused systemic inflammation and excess serum FGF23 in mice, suggesting that patients with FHH — at least those with GNA11 mutations — may be at risk for these complications.
- 26 March 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (9)
Open AccessGα11 deficiency increases fibroblast growth factor 23 levels in a mouse model of familial hypocalciuric hypercalcemia
Fibroblast growth factor 23 (FGF23) production has recently been shown to increase downstream of Gα q/11 -PKC signaling in osteocytes. Inactivating mutations in the gene encoding Gα 11 ( GNA11 ) cause familial hypocalciuric hypercalcemia (FHH) due to impaired calcium-sensing receptor signaling. We explored the effect of Gα 11 deficiency on FGF23 production in mice with heterozygous ( Gna11 +/– ) or homozygous ( Gna11 –/– ) ablation of Gna11 . Both Gna11 +/– and Gna11 –/– mice demonstrated hypercalcemia and mildly raised parathyroid hormone levels, consistent with FHH. Strikingly, these mice also displayed increased serum levels of total and intact FGF23 and hypophosphatemia. Gna11 –/– mice showed augmented Fgf23 mRNA levels in the liver and heart, but not in bone or bone marrow, and also showed evidence of systemic inflammation with elevated serum IL-1β levels. Furin gene expression was significantly increased in the Gna11 –/– liver, suggesting enhanced FGF23 cleavage despite the observed rise in circulating intact FGF23 levels. Gna11 –/– mice had normal renal function and reduced serum levels of glycerol-3-phosphate, excluding kidney injury as the primary cause of elevated intact FGF23 levels. Thus, Gα 11 ablation caused systemic inflammation and excess serum FGF23 in mice, suggesting that patients with FHH — at least those with GNA11 mutations — may be at risk for these complications.
- Open Access
- 14 June 2023
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 20 (1) , 1-17
Microglial cell response to experimental periodontal disease
Objectives: Microglial activation is critical for modulating the neuroinflammatory process and the pathological progression of neurodegenerative diseases, such as Alzheimer's disease (AD). Microglia are involved in forming barriers around extracellular neuritic plaques and the phagocytosis of β-amyloid peptide (Aβ). In this study, we tested the hypothesis that periodontal disease (PD) as a source of infection alters inflammatory activation and Aβ phagocytosis by the microglial cells. Methods: Experimental PD was induced using ligatures in C57BL/6 mice for 1, 10, 20, and 30 days to assess the progression of PD. Animals without ligatures were used as controls. Maxillary bone loss and local periodontal tissue inflammation associated with the development of PD were confirmed by morphometric bone analysis and cytokine expression, respectively. The frequency and the total number of activated microglia (CD45+ CD11b+ MHCII+) in the brain were analyzed by flow cytometry. Mouse microglial cells (1 × 105) were incubated with heat-inactivated bacterial biofilm isolated from the ligatures retrieved from the teeth or with Klebsiella variicola, a relevant PD-associated bacteria in mice. Expression of pro-inflammatory cytokines, toll-like receptors (TLR), and receptors for phagocytosis was measured by quantitative PCR. The phagocytic capacity of microglia to uptake β-amyloid was analyzed by flow cytometry. Results: Ligature placement caused progressive periodontal disease and bone resorption that was already significant on day 1 post-ligation (p < 0.05) and continued to increase until day 30 (p < 0.0001). The severity of periodontal disease increased the frequency of activated microglia in the brains on day 30 by 36%. In parallel, heat-inactivated PD-associated total bacteria and Klebsiella variicola increased the expression of TNFα, IL-1β, IL-6, TLR2, and TLR9 in microglial cells (1.6-, 83-, 3.2-, 1.5-, 1.5-fold, respectively p < 0.01). Incubation of microglia with Klebsiella variicola increased the Aβ-phagocytosis by 394% and the expression of the phagocytic receptor MSR1 by 33-fold compared to the non-activated cells (p < 0.0001). Conclusions: We showed that inducing PD in mice results in microglia activation in vivo and that PD-associated bacteria directly promote a pro-inflammatory and phagocytic phenotype in microglia. These results support a direct role of PD-associated pathogens in neuroinflammation.
- 14 June 2023
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 20 (1) , 1-17
Open AccessMicroglial cell response to experimental periodontal disease
Objectives: Microglial activation is critical for modulating the neuroinflammatory process and the pathological progression of neurodegenerative diseases, such as Alzheimer's disease (AD). Microglia are involved in forming barriers around extracellular neuritic plaques and the phagocytosis of β-amyloid peptide (Aβ). In this study, we tested the hypothesis that periodontal disease (PD) as a source of infection alters inflammatory activation and Aβ phagocytosis by the microglial cells. Methods: Experimental PD was induced using ligatures in C57BL/6 mice for 1, 10, 20, and 30 days to assess the progression of PD. Animals without ligatures were used as controls. Maxillary bone loss and local periodontal tissue inflammation associated with the development of PD were confirmed by morphometric bone analysis and cytokine expression, respectively. The frequency and the total number of activated microglia (CD45+ CD11b+ MHCII+) in the brain were analyzed by flow cytometry. Mouse microglial cells (1 × 105) were incubated with heat-inactivated bacterial biofilm isolated from the ligatures retrieved from the teeth or with Klebsiella variicola, a relevant PD-associated bacteria in mice. Expression of pro-inflammatory cytokines, toll-like receptors (TLR), and receptors for phagocytosis was measured by quantitative PCR. The phagocytic capacity of microglia to uptake β-amyloid was analyzed by flow cytometry. Results: Ligature placement caused progressive periodontal disease and bone resorption that was already significant on day 1 post-ligation (p < 0.05) and continued to increase until day 30 (p < 0.0001). The severity of periodontal disease increased the frequency of activated microglia in the brains on day 30 by 36%. In parallel, heat-inactivated PD-associated total bacteria and Klebsiella variicola increased the expression of TNFα, IL-1β, IL-6, TLR2, and TLR9 in microglial cells (1.6-, 83-, 3.2-, 1.5-, 1.5-fold, respectively p < 0.01). Incubation of microglia with Klebsiella variicola increased the Aβ-phagocytosis by 394% and the expression of the phagocytic receptor MSR1 by 33-fold compared to the non-activated cells (p < 0.0001). Conclusions: We showed that inducing PD in mice results in microglia activation in vivo and that PD-associated bacteria directly promote a pro-inflammatory and phagocytic phenotype in microglia. These results support a direct role of PD-associated pathogens in neuroinflammation.
- 18 November 2022
- Published by Elsevier in Brain Research
- Vol. 1799, 148171
Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer’s disease
- 18 November 2022
- Published by Elsevier in Brain Research
- Vol. 1799, 148171
Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer’s disease
- Open Access
- 6 July 2022
- Published by Springer Nature in Research Square
Dysregulation of Sphingosine-1-Phosphate (S1P) and S1P Receptor 1 Signaling in the 5xFAD Mouse Model of Alzheimer’s Disease
Sphingolipid-1-phosphate (S1P) and S1P receptors (S1PRs) play crucial roles in cellular events in the brain. Aberrant S1P metabolism has been identified in the brains of Alzheimer’s disease (AD) patients. Our recent studies have shown that treatment with fingolimod, an analog of sphingosine known to activate S1PRs in vivo, provides neuroprotective effects in 5xFAD mice, resulting in the reduction of Aβ neurotoxicity, inhibition of activation of microglia and astrocytes, and increased hippocampal neurogenesis. However, the pathways by which dysfunctional S1P and S1PR signaling may associate with the development of AD-like pathology remain unknown. In this study, we investigated the alteration of S1P and S1PR1 signaling in the brain of 5xFAD transgenic mice compared to non-transgenic wildtype (WT) littermates at 3, 8, and 14 months of age. Compared to WT mice, we found significantly decreased levels of S1P concomitant with decreased sphingosine kinases (SphKs), increased S1P lyase (S1PL), and increased S1PR1 in 8- and 14-month-old, but not in 3-month-old 5xFAD mice. Furthermore, we detected increased activation of the S1PR1 downstream pathway of Akt/mTor/Tau signaling in aging 5xFAD mice. Treatment with fingolimod from 1 to 8 months of age reversed the levels of S1P, SphKs, and S1PL, and that of S1PR1 and its downstream pathway of Akt/mTor/Tau signaling. Together the data reveal that dysregulation of S1P and S1PR signaling may associate with the development of AD-like pathology through Akt/mTor/Tau signaling.
- 6 July 2022
- Published by Springer Nature in Research Square
Open AccessDysregulation of Sphingosine-1-Phosphate (S1P) and S1P Receptor 1 Signaling in the 5xFAD Mouse Model of Alzheimer’s Disease
Sphingolipid-1-phosphate (S1P) and S1P receptors (S1PRs) play crucial roles in cellular events in the brain. Aberrant S1P metabolism has been identified in the brains of Alzheimer’s disease (AD) patients. Our recent studies have shown that treatment with fingolimod, an analog of sphingosine known to activate S1PRs in vivo, provides neuroprotective effects in 5xFAD mice, resulting in the reduction of Aβ neurotoxicity, inhibition of activation of microglia and astrocytes, and increased hippocampal neurogenesis. However, the pathways by which dysfunctional S1P and S1PR signaling may associate with the development of AD-like pathology remain unknown. In this study, we investigated the alteration of S1P and S1PR1 signaling in the brain of 5xFAD transgenic mice compared to non-transgenic wildtype (WT) littermates at 3, 8, and 14 months of age. Compared to WT mice, we found significantly decreased levels of S1P concomitant with decreased sphingosine kinases (SphKs), increased S1P lyase (S1PL), and increased S1PR1 in 8- and 14-month-old, but not in 3-month-old 5xFAD mice. Furthermore, we detected increased activation of the S1PR1 downstream pathway of Akt/mTor/Tau signaling in aging 5xFAD mice. Treatment with fingolimod from 1 to 8 months of age reversed the levels of S1P, SphKs, and S1PL, and that of S1PR1 and its downstream pathway of Akt/mTor/Tau signaling. Together the data reveal that dysregulation of S1P and S1PR signaling may associate with the development of AD-like pathology through Akt/mTor/Tau signaling.
- Open Access
- 29 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-10
Microglial response to experimental periodontitis in a murine model of Alzheimer’s disease
Periodontal disease (PD) has been suggested to be a risk factor for Alzheimer’s disease (AD). We tested the impact of ligature-induced PD on 5xFAD mice and WT littermates. At baseline, 5xFAD mice presented significant alveolar bone loss compared to WT mice. After the induction of PD, both WT and 5xFAD mice experienced alveolar bone loss. PD increased the level of Iba1-immunostained microglia in WT mice. In 5xFAD mice, PD increased the level of insoluble Aβ42. The increased level in Iba1 immunostaining that parallels the accumulation of Aβ in 5xFAD mice was not affected by PD except for a decrease in the dentate gyrus. Analysis of double-label fluorescent images showed a decline in Iba1 in the proximity of Aβ plaques in 5xFAD mice with PD compared to those without PD suggesting a PD-induced decrease in plaque-associated microglia (PAM). PD reduced IL-6, MCP-1, GM-CSF, and IFN-γ in brains of WT mice and reduced IL-10 in 5xFAD mice. The data demonstrated that PD increases neuroinflammation in WT mice and disrupts the neuroinflammatory response in 5xFAD mice and suggest that microglia is central to the association between PD and AD.
- 29 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-10
Open AccessMicroglial response to experimental periodontitis in a murine model of Alzheimer’s disease
Periodontal disease (PD) has been suggested to be a risk factor for Alzheimer’s disease (AD). We tested the impact of ligature-induced PD on 5xFAD mice and WT littermates. At baseline, 5xFAD mice presented significant alveolar bone loss compared to WT mice. After the induction of PD, both WT and 5xFAD mice experienced alveolar bone loss. PD increased the level of Iba1-immunostained microglia in WT mice. In 5xFAD mice, PD increased the level of insoluble Aβ42. The increased level in Iba1 immunostaining that parallels the accumulation of Aβ in 5xFAD mice was not affected by PD except for a decrease in the dentate gyrus. Analysis of double-label fluorescent images showed a decline in Iba1 in the proximity of Aβ plaques in 5xFAD mice with PD compared to those without PD suggesting a PD-induced decrease in plaque-associated microglia (PAM). PD reduced IL-6, MCP-1, GM-CSF, and IFN-γ in brains of WT mice and reduced IL-10 in 5xFAD mice. The data demonstrated that PD increases neuroinflammation in WT mice and disrupts the neuroinflammatory response in 5xFAD mice and suggest that microglia is central to the association between PD and AD.
- Open Access
- 6 March 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (3) , 408
A Preliminary Study of Cu Exposure Effects upon Alzheimer’s Amyloid Pathology
A large body of evidence indicates that dysregulation of cerebral biometals (Fe, Cu, Zn) and their interactions with amyloid precursor protein (APP) and Aβ amyloid may contribute to the Alzheimer’s disease (AD) Aβ amyloid pathology. However, the molecular underpinnings associated with the interactions are still not fully understood. Herein we have further validated the exacerbation of Aβ oligomerization by Cu and H2O2 in vitro. We have also reported that Cu enhanced APP translations via its 5′ untranslated region (5′UTR) of mRNA in SH-SY5Y cells, and increased Aβ amyloidosis and expression of associated pro-inflammatory cytokines such as MCP-5 in Alzheimer’s APP/PS1 doubly transgenic mice. This preliminary study may further unravel the pathogenic role of Cu in Alzheimer’s Aβ amyloid pathogenesis, warranting further investigation.
- 6 March 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (3) , 408
Open AccessA Preliminary Study of Cu Exposure Effects upon Alzheimer’s Amyloid Pathology
A large body of evidence indicates that dysregulation of cerebral biometals (Fe, Cu, Zn) and their interactions with amyloid precursor protein (APP) and Aβ amyloid may contribute to the Alzheimer’s disease (AD) Aβ amyloid pathology. However, the molecular underpinnings associated with the interactions are still not fully understood. Herein we have further validated the exacerbation of Aβ oligomerization by Cu and H2O2 in vitro. We have also reported that Cu enhanced APP translations via its 5′ untranslated region (5′UTR) of mRNA in SH-SY5Y cells, and increased Aβ amyloidosis and expression of associated pro-inflammatory cytokines such as MCP-5 in Alzheimer’s APP/PS1 doubly transgenic mice. This preliminary study may further unravel the pathogenic role of Cu in Alzheimer’s Aβ amyloid pathogenesis, warranting further investigation.
- Open Access
- 29 July 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-11
Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer’s disease
Lipid metabolism is abnormal in Alzheimer’s disease (AD) brain leading to ceramide and sphingosine accumulation and reduced levels of brain sphingosine-1-phosphate (S1P). We hypothesize that changes in S1P signaling are central to the inflammatory and immune-pathogenesis of AD and the therapeutic benefits of fingolimod, a structural analog of sphingosine that is FDA approved for the treatment of multiple sclerosis. We recently reported that the neuroprotective effects of fingolimod in 5xFAD transgenic AD mice treated from 1–3 months of age were greater at 1 mg/kg/day than at 5 mg/kg/day. Here we performed a dose-response study using fingolimod from 0.03 to 1 mg/kg/day in 5xFAD mice treated from 1–8 months of age. At 1 mg/kg/day, fingolimod decreased both peripheral blood lymphocyte counts and brain Aβ levels, but at the lowest dose tested (0.03 mg/kg/day), we detected improved memory, decreased activation of brain microglia and astrocytes, and restored hippocampal levels of GABA and glycerophosphocholine with no effect on circulating lymphocyte counts. These findings suggests that, unlike the case in multiple sclerosis, fingolimod may potentially have therapeutic benefits in AD at low doses that do not affect peripheral lymphocyte function.
- 29 July 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-11
Open AccessDual dose-dependent effects of fingolimod in a mouse model of Alzheimer’s disease
Lipid metabolism is abnormal in Alzheimer’s disease (AD) brain leading to ceramide and sphingosine accumulation and reduced levels of brain sphingosine-1-phosphate (S1P). We hypothesize that changes in S1P signaling are central to the inflammatory and immune-pathogenesis of AD and the therapeutic benefits of fingolimod, a structural analog of sphingosine that is FDA approved for the treatment of multiple sclerosis. We recently reported that the neuroprotective effects of fingolimod in 5xFAD transgenic AD mice treated from 1–3 months of age were greater at 1 mg/kg/day than at 5 mg/kg/day. Here we performed a dose-response study using fingolimod from 0.03 to 1 mg/kg/day in 5xFAD mice treated from 1–8 months of age. At 1 mg/kg/day, fingolimod decreased both peripheral blood lymphocyte counts and brain Aβ levels, but at the lowest dose tested (0.03 mg/kg/day), we detected improved memory, decreased activation of brain microglia and astrocytes, and restored hippocampal levels of GABA and glycerophosphocholine with no effect on circulating lymphocyte counts. These findings suggests that, unlike the case in multiple sclerosis, fingolimod may potentially have therapeutic benefits in AD at low doses that do not affect peripheral lymphocyte function.
- 1 June 2018
- Published by Elsevier in European Journal of Pharmacology
- Vol. 828, 9-17
Protective effects of 7,8-dihydroxyflavone on neuropathological and neurochemical changes in a mouse model of Alzheimer's disease
- 1 June 2018
- Published by Elsevier in European Journal of Pharmacology
- Vol. 828, 9-17
Protective effects of 7,8-dihydroxyflavone on neuropathological and neurochemical changes in a mouse model of Alzheimer's disease